These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7473081)

  • 41. The subject-by-formulation interaction in multivariate bioequivalence.
    Cao L; Mathew T
    J Biopharm Stat; 2007; 17(3):367-79. PubMed ID: 17479387
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bioequivalence and other unresolved issues in generic drug substitution.
    Meredith P
    Clin Ther; 2003 Nov; 25(11):2875-90. PubMed ID: 14693311
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessing bioequivalence using genomic data.
    Chow SC; Shao J; Li L
    J Biopharm Stat; 2004 Nov; 14(4):869-80. PubMed ID: 15587969
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bioequivalence studies: biometrical concepts of alternative designs and pooled analysis.
    Zintzaras E; Bouka P
    Eur J Drug Metab Pharmacokinet; 1999; 24(3):225-32. PubMed ID: 10716060
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-traditional study designs to demonstrate average bioequivalence for highly variable drug products.
    Patterson SD; Zariffa NM; Montague TH; Howland K
    Eur J Clin Pharmacol; 2001 Nov; 57(9):663-70. PubMed ID: 11791897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bioequivalence testing of immunosuppressants: concepts and misconceptions.
    Christians U; Klawitter J; Clavijo CF
    Kidney Int Suppl; 2010 Mar; (115):S1-7. PubMed ID: 20150904
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bioequivalence: switchability and scaling.
    Midha KK; Rawson MJ; Hubbard JW
    Eur J Pharm Sci; 1998 Apr; 6(2):87-91. PubMed ID: 9795020
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Carryover negligibility and relevance in bioequivalence studies.
    Ocaña J; Sanchez O MP; Carrasco JL
    Pharm Stat; 2015; 14(5):400-8. PubMed ID: 26175204
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Bioequivalence and generics of index drugs with narrow therapeutic margins].
    Le Corre P
    Presse Med; 2010 Feb; 39(2):169-76. PubMed ID: 19932591
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of average, population and individual bioequivalence in two- and four-period crossover studies.
    Wijnand HP
    Comput Methods Programs Biomed; 2003 Jan; 70(1):21-35. PubMed ID: 12468124
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Bioequivalence Approach for Generic Narrow Therapeutic Index Drugs: Evaluation of the Reference-Scaled Approach and Variability Comparison Criterion.
    Jiang W; Makhlouf F; Schuirmann DJ; Zhang X; Zheng N; Conner D; Yu LX; Lionberger R
    AAPS J; 2015 Jul; 17(4):891-901. PubMed ID: 25840883
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Subject-by-formulation interaction in bioequivalence: conceptual and statistical issues. FDA Population/Individual Bioequivalence Working Group. Food and Drug Administration.
    Hauck WW; Hyslop T; Chen ML; Patnaik R; Williams RL
    Pharm Res; 2000 Apr; 17(4):375-80. PubMed ID: 10870978
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Group sequential extensions of a standard bioequivalence testing procedure.
    Gould AL
    J Pharmacokinet Biopharm; 1995 Feb; 23(1):57-86. PubMed ID: 8576845
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.
    Kesselheim AS; Polinski JM; Fulchino LA; Isaman DL; Gagne JJ
    Drugs; 2015 Apr; 75(6):633-50. PubMed ID: 25822610
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of the repeated cross-over designs in assessing bioequivalence.
    Liu JP
    Stat Med; 1995 May 15-30; 14(9-10):1067-78; discussion 1079-80. PubMed ID: 7569501
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comment on so-called individual criteria of bioequivalence.
    Wellek S
    J Biopharm Stat; 1997 Mar; 7(1):17-21. PubMed ID: 9056583
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Bioequivalence and generic drugs. I. Studies of bioequivalence, considering the theoretical basis, design and use].
    Zapater P; Horga JF
    Rev Neurol; 1999 Dec 16-31; 29(12):1235-46. PubMed ID: 10652753
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tolerance intervals for assessing individual bioequivalence.
    Brown EB; Iyer HK; Wang CM
    Stat Med; 1997 Apr; 16(7):803-20. PubMed ID: 9131767
    [TBL] [Abstract][Full Text] [Related]  

  • 60. On assessment of bioequivalence under a higher-order crossover design.
    Chow SC; Liu JP
    J Biopharm Stat; 1992; 2(2):239-56. PubMed ID: 1300216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.